BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.21% | 18.16% | -2.80% | -31.39% | -21.76% |
| Total Depreciation and Amortization | 95.98% | 44.28% | 22.46% | -2.37% | -31.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -72.37% | -73.87% | -32.86% | 203.22% | 84.77% |
| Change in Net Operating Assets | -200.85% | -484.29% | 119.35% | 121.47% | 3,812.33% |
| Cash from Operations | -62.55% | -16.87% | 2.80% | -7.53% | 10.28% |
| Capital Expenditure | -16,614.81% | -95.35% | 58.00% | 21.88% | -17.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -37,866.67% | -13,867.44% | -27,154.00% | 21.88% | -17.39% |
| Total Debt Issued | 165.39% | 5.88% | 5.88% | 5.88% | 5.88% |
| Total Debt Repaid | 14.26% | 40.93% | 50.08% | 51.78% | 21.82% |
| Issuance of Common Stock | 184.47% | 81.25% | 72.75% | 90.88% | -41.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 392.77% | 166.50% | 179.02% | 203.18% | -44.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 237.41% | 539.80% | 50.58% | 2,503.22% | -226.08% |